Unfortunately, there are still no data about TF antibody glycodiversity after the vaccination with various TF-positive conjugates that could be a means to improve the IT efficacy and explain as well as avoid some controversies in their effect on tumor cells, including the possibility to enhance tumor cell proliferation [148]. The gene discussed is TF; the disease is neoplasm.